<SEC-DOCUMENT>0001689375-25-000002.txt : 20250203
<SEC-HEADER>0001689375-25-000002.hdr.sgml : 20250203
<ACCEPTANCE-DATETIME>20250203070522
ACCESSION NUMBER:		0001689375-25-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250203
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250203
DATE AS OF CHANGE:		20250203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entrada Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001689375
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813983399
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40969
		FILM NUMBER:		25580576

	BUSINESS ADDRESS:	
		STREET 1:		ONE DESIGN CENTER PLACE
		STREET 2:		SUITE 17-500
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-305-1825

	MAIL ADDRESS:	
		STREET 1:		ONE DESIGN CENTER PLACE
		STREET 2:		SUITE 17-500
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CycloPorters, Inc.
		DATE OF NAME CHANGE:	20161104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>trda-20250203.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f27e0ae3-18ce-4e0a-a8e9-267e4d92e528,g:b95f459f-c5e4-4f63-8a10-9a7ecd1e3c44,d:07c65818a6364331a220a93c241f36b6-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>trda-20250203</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001689375</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="trda-20250203.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-03</xbrli:startDate><xbrli:endDate>2025-02-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i07c65818a6364331a220a93c241f36b6_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 3, 2025</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ENTRADA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40969</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">81-3983399</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.181%"><tr><td style="width:1.0%"/><td style="width:37.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">One Design Center Place</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 17-500</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02210</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code) </span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">(857)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">520-9158</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">TRDA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-21">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07c65818a6364331a220a93c241f36b6_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7.01    Regulation FD Disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">On February 3, 2025, Entrada Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release titled &#8220;Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy.&#8221; A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">The information in this Item 7.01 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 8.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Events.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">On February 3, 2025, the Company announced the receipt of authorization from the United Kingdom&#8217;s Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product for a Phase 1/2 multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (&#8220;DMD&#8221;) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. ENTR-601-44 is Entrada&#8217;s lead product candidate within its Duchenne franchise and is being developed for the potential treatment of individuals with Duchenne who are exon 44 skipping amenable..</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">The Phase 1/2 trial&#8217;s primary objective is to evaluate the safety, tolerability and effectiveness of ENTR-601-44 in ambulatory patients with DMD who are exon 44 skipping amenable. The Company is on track to initiate the trial for ENTR-601-44 in the United Kingdom in the second quarter of 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%">Forward-Looking Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Current Report on Form 8-K contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company&#8217;s strategy, future operations, prospects and plans, objectives of management, expectations regarding the Company&#8217;s planned Phase 1/2 multiple ascending dose clinical study ENTR-601-44, including its initiation in the United Kingdom in Q2 2025, the ability to recruit for and complete a Phase 1/2 clinical trial for ENTR-601-44, expectations regarding the safety and therapeutic benefits of ENTR-601-44, the continued development and advancement of ENTR-601-44 for the potential treatment of DMD, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; or &#8220;would,&#8221; or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical and clinical studies; the timing of and the Company&#8217;s ability to submit and obtain regulatory clearance for Investigational New Drug application applications and initiate clinical trials; whether results from preclinical studies and clinical trials will be predictive of the results of later preclinical studies and clinical trials; whether the Company&#8217;s cash resources will be sufficient to fund the Company&#8217;s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in the Company&#8217;s filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;), including the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company&#8217;s views as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date of this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:99%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Exhibits.</span></div><div style="text-indent:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following exhibit relating to Item 7.01 of this Form 8-K shall be deemed to be furnished and not filed:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="trda-202523xpr.htm">Press Release issued by Entrada Therapeutics,&#160;Inc. on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="trda-202523xpr.htm">February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="trda-202523xpr.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="trda-202523xpr.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="trda-202523xpr.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="trda-202523xpr.htm">5</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07c65818a6364331a220a93c241f36b6_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entrada Therapeutics,&#160;Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February 3, 2025 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dipal Doshi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dipal Doshi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>trda-202523xpr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="idb58237fe8f64bfeadf8e1970e599ac7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:191px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1&#47;2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Company on track to initiate ELEVATE-44-201 in Q2 2025 &#8211;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing &#8211;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BOSTON, February 3, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq&#58; TRDA) today announced it had received authorization from the United Kingdom&#8217;s Medicines and Healthcare Products Regulatory Agency (MHRA) </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1&#47;2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">DMD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> gene amenable to exon 44 skipping. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The clearance by the MHRA marks a new phase in Entrada&#8217;s growth and, most importantly, moves us closer to realizing our commitment to families living with Duchenne muscular dystrophy,&#8221; said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics. &#8220;As the first authorization for our global MAD clinical study of ENTR-601-44 in patients, we are pleased to be initiating the study at what we believe to be an effective therapeutic dose. This is even more important since families living with Duchenne do not have time on their side as the progressive decline in function profoundly impacts the quality of life for patients and their care partners. It is this urgency that drives our work each day.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The MHRA authorization of ELEVATE-44-201 is an exciting development in the clinical progress of ENTR-601-44, a new and very encouraging treatment option for boys and young men living with Duchenne muscular dystrophy who are exon 44 skipping amenable,&#8221; said Francesco Muntoni, MD, Professor of Paediatric Neurology. &#8220;There is a significant unmet medical need in this population, with limited therapeutic options available. The unique properties of Entrada&#8217;s EEV-therapeutic candidates offer the potential to provide tangible benefits for people with this life-shortening disease.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ELEVATE-44-201 is a global, two-part, randomized, double-blind placebo-controlled Phase 1&#47;2 study evaluating the safety, tolerability and effectiveness of ENTR-601-44 in ambulatory patients with DMD who are exon 44 skipping amenable. Part A is a multiple ascending dose study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics, including exon skipping and dystrophin production in approximately 24 patients. Dosing will be administered every six weeks, with the planned doses across three cohorts anticipated to range from 6 mg&#47;kg up to 18 mg&#47;kg. Part B of the study is designed to further evaluate the optimal dose established in Part A for safety and efficacy, including patient reported outcomes and quality of life measures. Study participants may be eligible to enter an open label extension study (OLE), in which the safety, efficacy and tolerability of ENTR-601-44 will be evaluated over a longer period of time. The Company is on track to initiate ELEVATE-44-201 in Q2 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The MHRA authorization follows the completion of a Phase 1 clinical study to evaluate the safety and tolerability of a single dose of ENTR-601-44. This study demonstrated ENTR-601-44 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:191px"></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">was generally well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, electrocardiograms, physical exams or laboratory assessments. The study also demonstrated significant plasma concentration, muscle concentration and exon skipping.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About ENTR-601-44</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ENTR-601-44, a proprietary Endosomal Escape Vehicle (EEV&#8482;)-conjugated phosphorodiamidate morpholino oligomer (PMO), is the lead product candidate within Entrada&#8217;s Duchenne muscular dystrophy franchise from its growing pipeline of EEV-therapeutics. Each EEV-PMO therapeutic candidate has an oligonucleotide sequence designed and optimized for the specific subpopulation of interest. ENTR-601-44 is designed to address the underlying cause of Duchenne due to mutated or missing exons in the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">DMD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> gene. ENTR-601-44, an investigational therapy for the potential treatment of people living with Duchenne who are exon 44 skipping amenable, is being evaluated for its potential to restore the mRNA reading frame and allow for the translation of dystrophin protein that is slightly shortened but still functional.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Duchenne Muscular Dystrophy (DMD)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Duchenne muscular dystrophy (DMD) is a rare disease caused by mutations in the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">DMD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> gene, which encodes for the dystrophin protein. These mutations lead to inadequate dystrophin production. Dystrophin is essential to maintaining the structural integrity and function of muscle cells. Lack of functional dystrophin leads to progressive loss of muscle strength, impacting mobility and causing heart or respiratory complications that contribute to high mortality rates. An estimated 41,000 people in the U.S. and Europe have Duchenne.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Entrada Therapeutics</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company&#8217;s Endosomal Escape Vehicle (EEV&#8482;)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company&#8217;s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information about Entrada, please visit our website, </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.entradatx.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and follow us on </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LinkedIn</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada&#8217;s strategy, future operations, prospects and plans, objectives of management, the validation and differentiation of Entrada&#8217;s approach and EEV platform and its ability to provide a potential treatment for patients, expectations regarding Entrada&#8217;s planned Phase 1&#47;2 multiple ascending dose clinical study ENTR-601-44, including its initiation in the United Kingdom in Q2 2025, the expectations about the planned dosing levels of the planned Phase 1&#47;2 trial for ENTR-601-44 and their efficacy, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:191px"></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ability to recruit for and complete a global Phase 1&#47;2 trial for ENTR-601-44 and the anticipated number of patients to be enrolled, the potential of Entrada&#8217;s EEV product candidates, including the potential for ENTR-601-44 to be a transformative treatment option, and the continued development and advancement of ENTR-601-44 for the potential treatment of DMD, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; or &#8220;would,&#8221; or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including&#58; uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials&#59; uncertainties as to the availability and timing of results from preclinical and clinical studies&#59; the timing of and Entrada&#8217;s ability to submit and obtain regulatory clearance and initiate clinical trials&#59; whether results from preclinical studies or clinical trials will be predictive of the results of later preclinical studies and clinical trials&#59; whether Entrada&#8217;s cash resources will be sufficient to fund the Company&#8217;s foreseeable and unforeseeable operating expenses and capital expenditure requirements&#59; as well as the risks and uncertainties identified in Entrada&#8217;s filings with the Securities and Exchange Commission (SEC), including the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this press release represent Entrada&#8217;s views as of the date of this press release. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada&#8217;s views as of any date subsequent to the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor and Media Contact</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Caileigh Dougherty</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Head of Investor Relations &#38; Corporate Communications</font></div><div><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">cdougherty&#64;entradatx.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>trda-20250203.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f27e0ae3-18ce-4e0a-a8e9-267e4d92e528,g:b95f459f-c5e4-4f63-8a10-9a7ecd1e3c44-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:trda="http://www.entradatx.com/20250203" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.entradatx.com/20250203">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="trda-20250203_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="trda-20250203_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.entradatx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>trda-20250203_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f27e0ae3-18ce-4e0a-a8e9-267e4d92e528,g:b95f459f-c5e4-4f63-8a10-9a7ecd1e3c44-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_801e2a50-5bce-43af-b253-a63d3b7204b0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_81e7d7e9-3932-4f23-807c-bc0a2df819aa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3ca014d1-b659-4df6-a6cf-239f4ad804aa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2512ae4f-cf4e-4659-9fb3-3c844ae88b0a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4072861e-7b65-4c3e-8f13-9eea9992756e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_14748cf6-2813-44ed-9989-9696ee5354aa_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_3901da5f-079f-479a-a769-af1a92da410c_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_97c20f75-2daf-4477-88d2-009220368f05_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b6bfb481-abd6-44aa-b670-d7ca179756b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_99bd1805-2ec8-4c3e-83c1-3da4c289a14c_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_21800eda-802a-4aae-8673-158aebde4325_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a81272e5-496a-4768-bb6c-c764e059f181_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_670ca30f-fd1c-45dd-8eee-e77ad57dccc4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4f24cc23-8141-4545-aeec-fb6d5ce289dc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_35622c21-5685-477c-b6d5-514e82a2e5e0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d659e660-02fa-43c4-8219-55f23ad393f1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b4a281e3-0719-4cb4-b576-6785ead6d71c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ba66f7c3-777a-4938-a97b-e860160ca504_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ad85af03-e726-4d6e-a6da-715c4bb653aa_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_edba5188-3777-477e-9ef4-643bc00f4083_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_80981f5c-98d1-4645-942e-e3dea7317337_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_79b2843e-b11f-4b69-acb0-2b59330b18b0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8e378b65-9e44-4fc8-8100-961efc826c48_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5379b16c-dd85-4942-a3ef-deb63facbfbb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>trda-20250203_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f27e0ae3-18ce-4e0a-a8e9-267e4d92e528,g:b95f459f-c5e4-4f63-8a10-9a7ecd1e3c44-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.entradatx.com/role/Cover" xlink:type="simple" xlink:href="trda-20250203.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.entradatx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_41c05a59-a8a9-4bbe-a03c-4c0a90a109e3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_DocumentType_41c05a59-a8a9-4bbe-a03c-4c0a90a109e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_44a84abc-dabc-4313-98a4-f3ab555df2d8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_DocumentPeriodEndDate_44a84abc-dabc-4313-98a4-f3ab555df2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a6809c6a-52b8-4a19-86f0-e5d3c672031c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityRegistrantName_a6809c6a-52b8-4a19-86f0-e5d3c672031c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_45817111-8a80-4d54-b3b0-cbb1b67223bd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityIncorporationStateCountryCode_45817111-8a80-4d54-b3b0-cbb1b67223bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_dd216e7b-6e80-4dac-a9ef-91ffe5d9eb73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityFileNumber_dd216e7b-6e80-4dac-a9ef-91ffe5d9eb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dc47937e-af49-4cf3-b66e-7fc9ae2956a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityTaxIdentificationNumber_dc47937e-af49-4cf3-b66e-7fc9ae2956a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c123584d-a8da-4831-87be-12b331e189a4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityAddressAddressLine1_c123584d-a8da-4831-87be-12b331e189a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2f2abe45-4d4b-487d-af8b-28c589159748" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityAddressAddressLine2_2f2abe45-4d4b-487d-af8b-28c589159748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2515ab2b-87a1-48af-8f4e-519fd456a490" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityAddressCityOrTown_2515ab2b-87a1-48af-8f4e-519fd456a490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_09a5140b-96c6-4ac2-a276-fb12d10f94bb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityAddressStateOrProvince_09a5140b-96c6-4ac2-a276-fb12d10f94bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eeb3cd02-27a9-428d-bee5-0e3708081662" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityAddressPostalZipCode_eeb3cd02-27a9-428d-bee5-0e3708081662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8fc05b26-b302-44fb-8d2e-3159b3d92710" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_CityAreaCode_8fc05b26-b302-44fb-8d2e-3159b3d92710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7568fccf-def7-44c4-bc90-8cde6dcbdce4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_LocalPhoneNumber_7568fccf-def7-44c4-bc90-8cde6dcbdce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d56bdc55-ae9e-495f-bb5f-f18e1f8d3d18" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_WrittenCommunications_d56bdc55-ae9e-495f-bb5f-f18e1f8d3d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d88cc2e5-88b7-42cd-8a17-abe68d92c572" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_SolicitingMaterial_d88cc2e5-88b7-42cd-8a17-abe68d92c572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_701779aa-be89-4dea-86ce-9b2060d2491d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_PreCommencementTenderOffer_701779aa-be89-4dea-86ce-9b2060d2491d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_afdec38c-fda6-4dbb-8dc0-dca65b54b284" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_afdec38c-fda6-4dbb-8dc0-dca65b54b284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b566901b-931f-43a3-9340-69a554252fb5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_Security12bTitle_b566901b-931f-43a3-9340-69a554252fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e7454aa2-89c7-4941-b896-331811c3c293" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_TradingSymbol_e7454aa2-89c7-4941-b896-331811c3c293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1580b4f9-12e4-48f9-8025-cec5b65c2941" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_SecurityExchangeName_1580b4f9-12e4-48f9-8025-cec5b65c2941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ea507d9b-7d30-4a6e-9d81-ece17b5570b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityEmergingGrowthCompany_ea507d9b-7d30-4a6e-9d81-ece17b5570b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_efe34273-5d87-4abb-bbc8-45e99a734189" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityExTransitionPeriod_efe34273-5d87-4abb-bbc8-45e99a734189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_26ac00dc-56ee-405a-b46a-cbfc7fd3c5f4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_EntityCentralIndexKey_26ac00dc-56ee-405a-b46a-cbfc7fd3c5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0251f356-7189-403a-b5f9-49f10f6df584" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1619a80d-19a5-480a-b708-3e1a367c3ace" xlink:to="loc_dei_AmendmentFlag_0251f356-7189-403a-b5f9-49f10f6df584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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M@:*B8I24E,+&QC+2)DV:P,[.]D\9]J1)DVSL&]O2VKA]V)&4B+OZ#Z[V:(?
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M_>V[&:9KQO-;I?E%LB"%?,^G=%REE:O2-OH!8E85N(G9K9#'P8;.+[5_!$\
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I'\8[%>/5GVZL\K+4W?%\9H[YRW\!%T+A=^?6ER,     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45815400868400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 03, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  03,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENTRADA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3983399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Design Center Place<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 17-500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">520-9158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TRDA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001689375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "J.$-:!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *HX
M0UJ"O_.2[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( *HX0UJ97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ JCA#6N<.#(J!
M!   PQ$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( *HX0UJ?H!OPL0(  .(,   -              "
M <0,  !X;"]S='EL97,N>&UL4$L! A0#%     @ JCA#6I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  !@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="trda-20250203.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="trda-20250203.htm">trda-20250203.htm</File>
    <File>trda-20250203.xsd</File>
    <File>trda-20250203_lab.xml</File>
    <File>trda-20250203_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "trda-20250203.htm": {
   "nsprefix": "trda",
   "nsuri": "http://www.entradatx.com/20250203",
   "dts": {
    "inline": {
     "local": [
      "trda-20250203.htm"
     ]
    },
    "schema": {
     "local": [
      "trda-20250203.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "trda-20250203_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "trda-20250203_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.entradatx.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "trda-20250203.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "trda-20250203.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.entradatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001689375-25-000002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001689375-25-000002-xbrl.zip
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M(0_'G7?7? AL=LY&Y#(>TNC=K@3U WI7\,!TE/P_K./"^O2WD5TP#(,:*P/
MK>&J__FSNU<]F%YK#LAFK&49QA3MARSKT(\%D-J!U88TD:R3?3C(U)11V8Y^
MZ6!(Q0V0LQ\K%0\[2$WP!Q3W:&@GT?.9Y@FARU5#; 4LI?QL9MM<AJ;*_/-V
MJ]RN+FZJEEW]O*+'$UFC14L]427]#D""2/E0JI=F@+7+AY[$CU-$!I+I(*$^
M^C*=*@'4YQ-4-.2+^-K@0L4)P B8^/[,69WAB/V%'/'U_/2Z=T*NKH^O>U=K
M,<9KK/:JU_UZ>7I]VKLBQ^<GI/=']]?C\U]ZI/OE[.STZNKTR_G&@_ [E0/@
M&Q5'N^2DW"V#]]ILM+="/:S"PV_JPBP?$$YD''+_A](6'[]<GEDF6=D=S"([
MXQP;IP],?\OY-._QO3'>*S'>MJJ;UQ ",$&7O?-K<MF[^')YO?$&YR(5,J61
M(BHF5\S#^-D@WJV36!"WN>._WW@@XD#G@F#]J>"*P\"]>V\ (2 CQYXBT.RV
MZXVM8R4,N7#QERR)A2([V7=&(>AB4A%VASDQH9N9_[[S5.5[H<.YG@GRIF-R
M'YXX0QAB@*\Y/AT[8YC?85$>HH/B9WV14C$F]5V=;GM3W1NCNE^/QULK\?BZ
MV:E+=L,EYOO4.;1D/%@O'8'.O3P^.2;7O_8NCR]Z7Z]/NU>[Y/2\6UZ9&S=%
M[G=Z]Q34%H*.XBYRD F51";,P_R/3WA$N)($%!U(OWA82[\)V2L)V;;@M5XK
MU^KUI7A]K:$:JU#[(=)FU*LE]TB_><:?PVB<O+S(5Y^B!D\C+Q9@]O6&QY4"
M(]V-TTB)<3?VIRTX[@=AJE>Q1,1W.,[$=#? QV A'5&Q(+]NM8GR_X;H_<A#
M!IW[H!LMJIJ8C'>=1K6]UW[#51%7U_3^U&Y*>)H=IQ&W!\&\Z]3;K7J]O1QS
M/XXT[VB)Q/@IAKA$D#\A+)$^U]&5WIL J\Z+$OS^QV*AG6X\''(I,W!1G(AA
MBQ\-TM/R9?FJ3'K#)(S'3&API\6!G,?E]_.,_DV>^LNZ%7OULMMRU_8J]LO-
M:OM97(%:N]QL-Y]OJ+T7]2H,+E\IEEA7FQ_[OF!2VO\^PWANILGW2T=?(D9.
MF 2H2%?#BG4WWK<X#[EGO6*W-^),$:>6$:=5.KI*.1@==]]I5JM;09&0!7/:
M)Z?'!L;E3R17%SY^$=?Q*/>[VZ6C?\=2@76<(=,N>>(<VN'X(B[ Q>>ZPLKN
MI%1+1V?'RQ,@S\<2&R]T3_)O+88O@& T_%^>F C+XM>%L*!6<Y?+VY;JK+EM
M&>/Q6'Q@9BH1P&P\H2%A]\Q+%;_#A!4X/DRNX^=M*7L]@!]@$8(\\IZLX/0]
M7+"T!?L3DUSL/W]NU=S] TD4"UDRB,%-B+2[OXMQ3I@B_0@5C )]?=990\NA
M\CR&%Z>DK@9H;C7WW\]*W;K['Y]C8)H+7.YTS.K62T?-6M5IN\W6-V>/5R?N
MW@;1]CQ6Y#A)0A KX-C-3YE_C 70Q^;,A4Z P5=J=!5P84#,AB#X_&@@24AE
MMG,VGSG?UOWNK<@V;V$6_X7MB*DC&##O5F]KTR01,9A:3"GUXWO29V$\0H[&
M1N1[PSDMYQ,)>(B:EDM0NXI%/K"[BH'CAVFH:,3B5(9C(JGB,ACKU^T+<1]H
M;+(5=B^]L.F4PC@@2M$X:PN D^(1OH<I98YI'ME9E7&WA4UKY79[.9>NS/"-
M<LM=B>&?*89:*QWV.PR,@\MO<WM6-[J_"ZZ -S%%F$8V1R8?/0C@-DI'\?,F
MWK\9=<_J-UJT  Q%O)"D4)]SF8;,R'JCUK1B.5/W@N4N.^X^Z7Z\)+5ZM0P=
M%^0>YU2KVUBB6S<C,;#93'T%UL8#$D0W9Z"F05>'CW-T\P?GZ E.R- BY0%V
M=AL4G/H"1T^5;^7\W !UJ7N^L?0+L/2%8*BC\;B3+M!%=T)\"0(,DQYC[;T?
MG+4!-XY70,YJ6MMM^$YMI__>?%N)V\T+;_S^\OQ^*F7*Q%I<O__&]8NXOLZ<
MQHZW!M?;%];9-"T>"DQBR7%!'<%"BCG)N6."D]A#AQ'5R2NT#W%CJN9?>>QD
MH?D[$!.BWC"G+QB]=6@ QJ]#PQ$=2Q2J[W.><3.BUH(K:B)()B &31XL,I^H
M0QM; C.L%DK6MB>4?$)1W,//&]7EN]<K+PH::NM._MT7]?(U?Z^Z%W6-Q_M-
M2;\W(%Y(I?SQ]TT>0(6@N%JMZJ[&PWX<[OP=-I$6(^/<EGYKMF#64)K*L8B,
M!AR>3M3K.GN-5D5J#3J5)"WF2;>@[FJ-R-Q8I+%;ZVMIR[VU5ND(_3U Z)6*
MO=M=\M]:N;LDH8+<T3!E),$K&@;?5AW["%_^_0AB!=W(>$Z--FB RY.'2Q7>
M$/UDSL\<;7-@9K8T'+7+=%5XK0JT %?LG$J?_D5^">,^#<D9%;=,/5[GL.';
M*J>1C_$*(_TQ\?06"ZSK%G0JTY6Z,UL?7!)8(@0[N/0;<B/BD1I@V)/@=@B5
MQ&<!3*'/XA2RL]4FF3^2.#F)6"<[V''_P*1HL]Y<G^5)\"P/;F$6(JA:WZDM
M&''1(<=L:!U(3=XKC%U>8Z?F-2C46XSMZ>W1%TLB/*GP*P/A%PU!UP"P*'^@
M1#JYZL@M'=T_]>3D:TE3L$0^L/9CH;#QN2W& 8@2"R$R!%&*8ATGII+I7H!H
MNY&)EWSI*)V8ZX<0GWJN<(R3ZROA4"PC@ U:!+OC$MX# :61A\EGZGEX2 8[
MXT5D/A6^-%N8_M(@M;Y#IX/4HN"5MXHQ[Z]S+)I#OX_?P%5;EM5ZJYCX,2HF
MOO'^H@U)OZU^N]A^?KO8*Z;LT/]R@$D$]51'ID/@J'&&>0=3OYUF(^-;4*7
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MGJ1@M:.(P;#2 W(+<C(&BQTG@W'98H <@W))\M*@:2R UQFD(N)R *  [ S
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MTS"A#_HIUO OG[!@*_O&1 *]T@35D9P0Y2&.+-(%UZ"!+*#5*NE5R;5>Y/I
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M(=N=YGT2;7X:9^;1NU>;9]+5+SF_>_4_4$L#!!0    ( *HX0UIOJN@G 0<
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M>:-%_=WB!7D7>.#DX.&'=M/^@^;DX']02P,$%     @ JCA#6F$=)@W%$0
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MB3?SN4X@ 07*#NR=B*B.,\<*@*=C+1NXBJ BF;/<S"BZS\X_$86]($**@Z,
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M$:0TKG][$\X.UXY8.A)^9<84]B,!EP!9Q;!(**FIH8_Q#&.E0$Z9J)D9@X?
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M*Q8  '1R9&$M,C R-3 R,#,N>'-D4$L! A0#%     @ JCA#6GP)1SRN"@
MF5L  !4              ( !N1@  '1R9&$M,C R-3 R,#-?;&%B+GAM;%!+
M 0(4 Q0    ( *HX0UIOJN@G 0<  !$U   5              "  9HC  !T
M<F1A+3(P,C4P,C S7W!R92YX;6Q02P$"% ,4    " "J.$-:81TF#<41  !]
M00  $@              @ '.*@  =')D82TR,#(U,C-X<'(N:'1M4$L%!@
0   %  4 1 $  ,,\      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>trda-20250203_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="trda-20250203.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <startDate>2025-02-03</startDate>
            <endDate>2025-02-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001689375</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-02-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ENTRADA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">81-3983399</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">One Design Center Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 17-500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">520-9158</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">TRDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-22">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
